---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-018302"
form_type: "8-K"
ticker: "NXGL"
cik: "0001468929"
company_name: "NEXGEL, INC."
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:05:36.970640+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# NexGel closes Celularity regenerative biomaterials acquisition; expects revenue to triple to ~$35M

## Summary
- Acquired Celularity's regenerative biomaterials portfolio for $13.3M ($8.3M cash + $5M convertible note); closed April 17, 2026.
- Raised $6.9M via convertible notes (10% interest, 18-month, $0.60 conversion) and warrants (5-year, $0.80 strike) to fund the deal.
- Strategic partner Sequence LifeScience invests $5.5M; will serve as contract manufacturer and collaborate on new products.
- Transaction expected to triple annual revenue to ~$35M pro-forma and be immediately accretive to profitability.
- Launched BioNX Surgical division; planned 510(k) filings in 2026, 2027, 2028 for three new products.

## SEC filing metadata
- accession: 0001493152-26-018302
- form_type: 8-K
- ticker: NXGL
- cik: 0001468929
- company_name: NEXGEL, INC.
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/0001493152-26-018302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-018302
- JSON: https://secwatch.observer/filing/0001493152-26-018302.json
- Plain text: https://secwatch.observer/filing/0001493152-26-018302.txt

## Source-grounded claims
- claim_id: 31d77a24645b1150e1fd7564b0b540a95c64d7f1
  claim: NEXGEL, INC. incurred convertible notes of original principal amount of $5,000,000 with Celularity Inc. at 10% per annum maturing eighteen (18) months following the issuance date.
  evidence_excerpt: a convertible promissory note issued by the Company to Celularity in the original principal amount of $5,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/0001493152-26-018302-index.htm
- claim_id: 84330190c7c86b950bf83cb1eb76633bc35cf33f
  claim: NEXGEL, INC. incurred convertible notes of aggregate original principal amount of $6,900,000 with Buyers at 10% per annum maturing eighteen (18) months following the issuance date.
  evidence_excerpt: the Company issued and sold to the Buyers (i) unsecured convertible promissory notes in the aggregate original principal amount of $6,900,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/0001493152-26-018302-index.htm
- claim_id: ad0036c2fb907d0283cc778e0ab363aea15b9ab0
  claim: NEXGEL, INC. completed an acquisition involving Celularity Inc. for $13,300,000 (closed 2026-04-17).
  evidence_excerpt: the grant of rights and the transfer of assets contemplated by the License Agreement, the Company agreed to pay or deliver to Celularity aggregate consideration in the amount of $13,300,000, consisting of (i) an upfront cash payment of $8,300,000, paid on the Transaction Commencement Date (as defined in the License Agreement) in accordance with the flow of funds
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/0001493152-26-018302-index.htm
- claim_id: 63ba7fa8bdc36c1d32adabc762e3400dc0a68a18
  claim: NEXGEL, INC. entered into Asset Purchase and Exclusive License Agreement with Celularity Inc. (effective 2026-03-06).
  evidence_excerpt: on March 6, 2026, NexGel, Inc. (the “ Company ”) entered into an Asset Purchase and Exclusive License Agreement (the “ Original License Agreement ”) with Celularity Inc. (“ Celularity ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/0001493152-26-018302-index.htm
- claim_id: cb76574190358a1b9eeaa8c168ce83150164c550
  claim: NEXGEL, INC. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate original principal amount of $6,900,000 (effective 2026-04-17).
  evidence_excerpt: On April 17, 2026, the Company entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Buyers ”), pursuant to which the Company issued and sold to the Buyers (i) unsecured convertible promissory notes in the aggregate original principal amount of $6,900,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/0001493152-26-018302-index.htm
- claim_id: e8f9376ac4a24402daf92cb39f34d0d948ee0c21
  claim: NEXGEL, INC. amended Amendment No. 1 to Asset Purchase and Exclusive License Agreement with Celularity Inc. valued at aggregate consideration in the amount of $13,300,000 (effective 2026-04-17).
  evidence_excerpt: On April 17, 2026, the Company and Celularity entered into Amendment No. 1 to the Original License Agreement (the “ Amendment ” and, together with the Original License Agreement, the “ License Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468929/000149315226018302/0001493152-26-018302-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.